Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

LatviaBack to Latvia

Clinical trials in Riga – page 12

203 clinical trials in Riga, Latvia across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Riga at a glance
203
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

203 trials in Riga

Open in trial search

Bladder cancer

Not recruiting

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Poloxamer 407
  • Sponsor:Urogen Pharma Ltd.

Abdominal infection+3

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Neovascular age-related macular degeneration

Not recruiting

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Urinary tract infection+1

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Neovascular age-related macular degeneration

Not recruiting

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Opthea Limited

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Bicycletx Limited

Endocrine ophthalmopathy

Not recruiting

Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Pemphigoid

Not recruiting

Study on Efgartigimod Alfa and Prednisone for Adults with Bullous Pemphigoid

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:LatviaLatvia
  • Participants:0–17 years
  • Substances:Dimenhydrinate
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Rifamycin Sodium
  • Sponsor:Cosmo Technologies Limited

Other cities in Latvia

The busiest research cities in the country

All 19 cities in Latvia

Clinical research in Riga

What the registry says about research in the country

01 Immunology & Vaccines

Research focusing on vaccine development and immune responses, including studies of combined vaccines for childhood diseases and immune system modulation in various conditions.

  • Measles-Mumps-Rubella-Varicella vaccine studies
  • Primary Immune Thrombocytopenia treatments
  • Novel immunotherapy approaches
02 Metabolic & Endocrine Disorders

Investigations into metabolic conditions and hormone-related disorders, with emphasis on treatment innovations and management strategies.

  • Glucagon response studies
  • Hypertriglyceridemia management
  • Post-menopausal osteoporosis treatment
03 Inflammatory Conditions

Clinical research targeting various inflammatory diseases, including dermatological and rheumatological conditions.

  • Psoriatic arthritis treatments
  • Plaque psoriasis therapies
  • Ulcerative colitis interventions
04 Oncology & Neurology

Studies focusing on innovative treatments for cancer and neurological disorders, including targeted therapies and combination approaches.

  • Non-small cell lung cancer treatments
  • Glioblastoma therapy
  • Dravet Syndrome management
05 Respiratory & Cardiovascular

Research into pulmonary conditions and heart-related disorders, exploring new therapeutic approaches.

  • Pulmonary arterial hypertension
  • Asthma treatment innovations
  • Heart failure interventions
Back to LatviaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.